Clinical Trials Logo

Myelofibrosis clinical trials

View clinical trials related to Myelofibrosis.

Filter by:

NCT ID: NCT05762874 Not yet recruiting - Myelofibrosis Clinical Trials

Ruxolitinib in Patients With Myelofibrosis

Start date: March 2023
Phase:
Study type: Observational

Prospective study to evaluate the response of myelofibrosis patients to ruxolitinib and it's adverse events on patients (1 year observational study).

NCT ID: NCT05710211 Not yet recruiting - Myelofibrosis Clinical Trials

Clonal Architecture of ASXL1-mutated Myelofibrosis

CLONEMF
Start date: March 2023
Phase: N/A
Study type: Interventional

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

NCT ID: NCT05665192 Recruiting - Myelofibrosis Clinical Trials

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Start date: August 2, 2021
Phase:
Study type: Observational

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

NCT ID: NCT05582083 No longer available - Myelofibrosis Clinical Trials

Managed Access Program for Momelotinib in Myelofibrosis

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

NCT ID: NCT05569538 Recruiting - Myelofibrosis Clinical Trials

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with myelofibrosis.

NCT ID: NCT05535764 Recruiting - Myelofibrosis Clinical Trials

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

ATIOM
Start date: March 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05447260 Recruiting - Myelofibrosis Clinical Trials

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Start date: June 10, 2022
Phase: Phase 4
Study type: Interventional

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

NCT ID: NCT05444972 Completed - Myelofibrosis Clinical Trials

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

METER
Start date: August 23, 2022
Phase:
Study type: Observational

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

NCT ID: NCT05423691 Recruiting - Myelofibrosis Clinical Trials

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

TREG108
Start date: December 27, 2022
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib